In our patients, higher aTreg percentages among FOXP3+CD4+ T cells at the start of therapy were associated with a disease course characterised by more frequent serious infections during the follow-up with our patients with CLL. This evidence concerns the gene FOXP3 and B-cell chronic lymphocytic leukemia.